Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 8, Issue 10, Pages 794-805Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2875
Keywords
-
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059699] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL059699, R01 HL059699-11] Funding Source: Medline
- NIDDK NIH HHS [P01 DK038226, P01 DK038226-210011] Funding Source: Medline
Ask authors/readers for more resources
The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions. These endogenous lipid mediators are broken down into diols by soluble epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial cardiovascular properties of EETs. sEH inhibitors (sEHIs) that are based on 1,3-disubstituted urea have been rapidly developed, and have been shown to be antihypertensive and anti-inflammatory, and to protect the brain, heart and kidney from damage. Although challenges for the future exist-including improving the drug-like properties of sEHIs and finding better ways to target sEHIs to specific tissues-the recent initiation of the first clinical trials of sEHIs has highlighted the therapeutic potential of these agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available